GlassScriptPhysician profile
Michael Earl May
NPI 1184011470
$1,121.27
in general payments reported to CMS, 2019-2025
11 companies · $14.18 in 2025
The $14.18 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $285 · 2022: $30.82 · 2025: $14.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $574.38 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $227.41 | 2019 | |
| Celgene Corporation | $180.18 | 2019 | |
| Incyte Corporation | $26.71 | 2019-2025 | Pemazyre |
| Pharmacyclics LLC, An Abbvie Company | $24.11 | 2019-2020 | |
| Verastem, INC. | $17.86 | 2020 | |
| Bausch Health US, LLC | $15.85 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.63 | 2020 | |
| Currax Pharmaceuticals LLC | $14.97 | 2022 | |
| Jazz Pharmaceuticals INC. | $12.63 | 2019 | |
| Daiichi Sankyo INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.